Role of interleukin-2 and interleukin-6 in the mitogen responsiveness of T cells from patients with 'common-variable' hypogammaglobulinaemia.
We have assessed the ability of interleukin-2 (IL-2) and interleukin-6 (IL-6) to augment the proliferative response of T lymphocytes from 'common-variable' hypogammaglobulinaemia (CVH) patients and from normal controls, to the mitogens phytohaemagglutinin (PHA) and OKT3. We show that with cells from the control group and from those patients whose T cells respond to PHA within the control range, both IL-2 and IL-6 will significantly augment the response to OKT3. However, in those patients with a T cell defect in which the PHA response is below the control range, neither IL-2 nor IL-6 could restore the PHA or OKT3 response to normal. Responses to IL-2 or IL-6 alone were always in or above the control range.
North
M E
ME
Immune Deficiency Diseases Research Group, Clinical Research Centre, Harrow, England.
Webster
A D
AD
Farrant
J
J
D000361:Agammaglobulinemia / Q000276:immunology* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology / Q000502:physiology*; D015850:Interleukin-6 / Q000494:pharmacology / Q000502:physiology*; D008934:Mitogens / Q000494:pharmacology*; D008938:Mitosis; D016853:Muromonab-CD3; D010835:Phytohemagglutinins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D015850:Interleukin-6; D008934:Mitogens; D016853:Muromonab-CD3; D010835:Phytohemagglutinins; D011994:Recombinant Proteins